Abstract 1621P
Background
Erdafitinib (erda) is an oral selective pan-FGFR tyrosine kinase inhibitor approved for treatment of locally advanced or metastatic urothelial carcinoma in adults with susceptible FGFR3/2alt who have progressed during or after ≥1 line of platinum-based chemotherapy. Interim results from the RAGNAR study demonstrated tumor agnostic efficacy in patients (pts) with advanced solid tumors with predefined FGFRalt after failure of standard therapies (tx) (Loriot et al, ASCO 2022 ). Here we report results on pts with pancreatic cancer in RAGNAR.
Methods
Pts with advanced or metastatic pancreatic cancer with prespecified FGFR1-4alt (mutations or fusions), disease progression after ≥1 line of systemic tx, and who exhausted standard tx received oral erda until disease progression or intolerable toxicity. Primary end point is objective response rate (ORR) by independent review committee (IRC). Secondary endpoints include duration of response (DOR), disease control rate (DCR), progression-free survival (PFS), overall survival (OS), and safety.
Results
At data cutoff (median survival f/u 15.24 mo), 18 pts with pancreatic cancer received erda. Median age was 60.5 y (range 34-78); 17 (94.4%) had visceral metastases; median 3 prior lines of systemic tx (range 1-9); 1 (5.6%) responded to last line of tx. All 18-pts had FGFR fusions (14 FGFR2, 4 FGFR1); none had FGFR mutations. None of the pts had KRAS co-alterations. ORR by IRC was 55.6% (95% CI 30.8-78.5). Median time to onset of response was 1.45 mo. Responses were observed in pts with FGFR1 and FGFR2 fusions. Median DCR was 94.4%. Median DOR, PFS and OS were 7.1 mo, 7.0 mo, and 19.7 mo respectively. Investigator-assessed efficacy data were comparable to IRC. The most common adverse events (AEs) were dry mouth (72%), diarrhea (67%), stomatitis (67%), dry skin (67%), hyperphosphatemia (56%), and fatigue (50%); 5 (28%) had serious AEs; 2 (11%) discontinued erda due to AEs. No treatment-related deaths were observed.
Conclusions
Erda demonstrated robust and clinically meaningful activity in pancreatic cancer pts with FGFRalt. Safety data were consistent with erda safety profile.
Clinical trial identification
NCT04083976.
Editorial acknowledgement
Legal entity responsible for the study
Janssen Research & Development.
Funding
Janssen Research & Development.
Disclosure
S. Pant: Financial Interests, Personal, Advisory Role: Zyemworks, Ipsen, Novatris, Janssen; Financial Interests, Institutional, Research Funding: Mirati Therapeutics, Lilly, Xencor, Novartis, Regenix, Bristol Myers Squibb, Astellas Pharma, Purple Biotech, 4D Pharma, Boehringer Ingelheim, NGM Biopharmaceuticals, Janssen, Arcus Biosciences, Elicio Therapeutics. D. Arnold: Financial Interests, Personal, Speaker, Consultant, Advisor: ACE Oncology, Amgen, Art Tempi Media, AstraZeneca, Bayer, Boston Scientific, Bristol Myers Squibb, Personal Aptitude Health, Clinical Care Options (COO), CRA International, Eli Lilly, Hexal, IMedex Ipsen, IQVIA, Ketchum, MedAhead, Merck, Merck, Sh; Financial Interests, Personal, Leadership Role: OncoLytics (Project Lead). Maria Alsina. Consultancy/advisory role and honoraria: Amgen, Bristol Myers Squibb, MSD, Lilly, Servier. Markus Moehler. Consultancy/advisory role and honoraria: Amgen, Bristol Myers Squibb, Lilly, MCI Group, Merck, MSD, . J. Tabernero: Financial Interests, Personal, Speaker, Consultant, Advisor, Advisory/Consultancy Fees: Bosch Health Campus (BHC), Karolinska Comprehensive Cancer Centre, Oncode Institute, Oslo University Hospital Comprehensive Cancer Center (OUH CCC),Array Biopharma, AstraZeneca, Bayer, Boehringer Ingelheim, Cardiff Oncology, Chugai, Daiichi S; Financial Interests, Personal, Other, Honoraria: Imedex/HMP, Medscape Education, MJH Life Sciences, PeerView Institute for Medical Education and Physicians Education Resource (PER); Financial Interests, Personal, Member of Board of Directors: Cancer Core Europe, Horizon Europe Cancer Mission, Spanish Association Against Cancer-AECC; Financial Interests, Personal, Leadership Role: Institute for Health Research INCLIVA Clinical Hospital of Valencia, IdiSNA Universidad de Navarra, Spanish National Cancer Research Center (CNIO), European Organization for Research and Treatment of CancerEORTC, World Innovative Networking (WIN; Financial Interests, Personal, Principal Investigator: Array Biopharma Inc, AstraZeneca Pharmaceuticals LP, BeiGene, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Debiopharm International SA, F. Hoffmann-La Roche Ltd, Genentech Inc, HalioDX Non-financial SAS, Hutchison MediPharma International; Financial Interests, Personal, Other, President: Oncology Master PlanCatalonia Department of Health; Financial Interests, Personal, Other: Oncology Master PlanCatalonia Department of Health (President), Advisory Committee on Pharmaceutical Provision Financing under the Spanish Government (Advisory Committee), Array Biopharma Inc (Coordinating PI & Steering Committee Member, Clini). Y. Loriot: Financial Interests, Personal, Speaker, Consultant, Advisor: Astellas Pharma, AstraZeneca, Bristol Myers Squibb, Immunomedics, Janssen; Financial Interests, Institutional, Speaker, Consultant, Advisor: MSD Oncology; Financial Interests, Personal, Other, Travel reimbursment: Astellas, AstraZeneca, Janssen Oncology, MSD Oncology, and Roche; Financial Interests, Institutional, Research Funding: Astellas Pharma, AstraZeneca, Basilea, Bristol Myers Squibb, Exelixis, Gilead Sciences, Incyte, Janssen Oncology, Merck KGaA, MSD Oncology, Nektar, Pfizer, Roche, Sanofi, and Taiho Pharmaceutical. G.M. Haag: Financial Interests, Personal, Research Grant: MSD; Financial Interests, Personal, Speaker, Consultant, Advisor: Bristol Myers Squibb, MSD Sharp & Dohme, Lilly, Novartis, Daiichi Sankyo, Servier; Financial Interests, Personal, Other, Honoriaria: Servier, MSD Sharp and Dohme; Financial Interests, Personal, Other, Support for attending Meetings/Travel: Servier, Bristol Myers Squibb, Lilly. D. Palmer: Financial Interests, Personal, Speaker, Consultant, Advisor: MSD, AstraZeneca, Eisai, Sirtex Medical, Roche, Boston Scientific, Viatris Research Funding: BMS, Bayer, Sirtex Medical, AstraZeneca, NuCana; Financial Interests, Institutional, Speaker, Consultant, Advisor: Bristol Meyers-Squibb. H. Prenen: Financial Interests, Institutional, Advisory Board: Amgen, AstraZeneca, Roche, Bayer, Ipsen, Sanofi. I. Lugowska: Financial Interests, Institutional, Research Grant: Agenus, Roche; Financial Interests, Personal, Writing Engagement: ESMO, Roche; Financial Interests, Personal and Institutional, Coordinating PI: MSD, Roche, BMS, Janssen, Astra, Amgen, RyVu, Incyte, Siropa, Menarini, Celon, Pfizer, Agenus, Rhizen. A. Cervantes: Financial Interests, Institutional, Research Grant: Actuate Therapeutic, Adaptimmune, Affimed Amgen, Astellas Pharma, AstraZeneca, Lilly, MedImmune, Merck, MSD, Natera, Novartis, Ribon Therapeutics Roche, Takeda, Bayer, F. Star Therapeutics, Genentech, Gilead, Janssen; Financial Interests, Personal, Invited Speaker: Amgen, Foundation Medicine, Merck, Roche; Financial Interests, Institutional, Advisory Board: AnHeart Therapeutics GSK Merck Roche Transgene, AbbVie, Amgen; Financial Interests, Personal, Officer, ESMO President: ESMO; Financial Interests, Personal, Other, Associate Editor: ESMO Open, Annals of Oncology; Financial Interests, Personal, Other, Editor In Chief: Cancer Treatment Reviews; Financial Interests, Personal, Advisory Board, Scientific Director: INCLIVA Biomedical Research Institute. M. Gutierrez: Financial Interests, Personal, Speaker, Consultant, Advisor, Consultancy Fees: Celularity and Guardant. H. Sweiti, S. Thomas, S. Triantos, L. Crow: Financial Interests, Personal, Other, Employment: Janssen; Financial Interests, Personal, Stocks/Shares: Janssen. C. Hammond, S. Najmi: Financial Interests, Personal, Advisory Board, Employment: Janssen. M.H.H. Schuler: Financial Interests, Personal, Speaker, Consultant, Advisor, Consultancy Fees: Amgen, AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, GSK, Janssen Oncology, Merck, Novartis, Roche, Sanofi, and Takeda; Financial Interests, Personal, Other, Honoraria: Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Janssen-Cilag, and Novartis; Financial Interests, Institutional, Research Funding: AstraZeneca and Bristol Myers Squibb; Financial Interests, Institutional, Royalties: PCR. All other authors have declared no conflicts of interest.
Resources from the same session
1579P - Gender differences and worse metastatic survival outcomes in young adult patients with oesophagogastric cancer: 12-year data from a Czech comprehensive cancer center
Presenter: Tomás Sokop
Session: Poster session 22
1580P - Early onset oesophageal adenocarcinoma: A separate biological entity?
Presenter: Dharmesh Valand
Session: Poster session 22
1581P - Total neoadjuvant chemotherapy with FOLFIRINOX regimen in patients with resectable locally advanced gastric and gastroesophageal junction cancer
Presenter: Maria Sedova
Session: Poster session 22
1582P - Gastroesophageal adenocarcinoma in young adults: Retrospective analysis of clinical and molecular features
Presenter: Daniel Acosta Eyzaguirre
Session: Poster session 22
1583P - Intraperitoneal chemotherapy for peritoneal metastases of gastric origin: A systematic review and meta-analysis
Presenter: Niels Guchelaar
Session: Poster session 22
1585P - The impact of platinum-induced peripheral neuropathy (PN) in first-line treatment on PN and efficacy in second-line paclitaxel (PTX)-based chemotherapy for unresectable advanced gastric cancer (AGC): A prospective observational multicenter study - IVY study
Presenter: Yoshiyasu Kono
Session: Poster session 22
1587P - Analysis of survival outcomes according to start timing of adjuvant chemotherapy in patients with gastric cancer: A retrospective nationwide cohort study
Presenter: Tae-Hwan Kim
Session: Poster session 22
1588P - Analysis of risk factors of anastomotic leakage after minimally invasive esophagectomy with circular cervical anastomosis
Presenter: ming lu
Session: Poster session 22